Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...
Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
A new formulation of the best-selling cancer drug, Keytruda, appears to deliver similar blood levels of the medicine when ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...
A roundup of recent health news, covering the U.S. Supreme Court's decision on a patent dispute, a Wyoming judge's abortion ...
Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...
The ongoing trial is assessing the drug's performance both as a standalone therapy and in combination with the programmed cell death protein 1 (PD-1) checkpoint inhibitor Keytruda. It is structured ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval of its ...